Telesis Bio Inc.
Find Ratings ReportsTELESIS BIO INC's gross profit margin for the third quarter of its fiscal year 2023 has increased when compared to the same period a year ago. Even though sales decreased, the net income has increased. TELESIS BIO INC has strong liquidity. Currently, the Quick Ratio is 1.85 which shows the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.
During the same period, stockholders' equity ("net worth") has decreased by 12.79% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
Income Statement | Q3 FY23 | Q3 FY22 |
---|---|---|
Net Sales ($mil) | 5.56 | 6.68 |
EBITDA ($mil) | -9.49 | -10.8 |
EBIT ($mil) | -10.12 | -11.25 |
Net Income ($mil) | -10.63 | -12.31 |
Balance Sheet | Q3 FY23 | Q3 FY22 |
---|---|---|
Cash & Equiv. ($mil) | 41.63 | 49.93 |
Total Assets ($mil) | 105.03 | 88.14 |
Total Debt ($mil) | 49.92 | 21.38 |
Equity ($mil) | 46.49 | 53.31 |
Profitability | Q3 FY23 | Q3 FY22 |
---|---|---|
Gross Profit Margin | 65.19 | 61.6 |
EBITDA Margin | -170.57 | -161.76 |
Operating Margin | -181.9 | -168.55 |
Sales Turnover | 0.29 | 0.24 |
Return on Assets | -36.34 | -59.93 |
Return on Equity | -83.65 | -99.1 |
Debt | Q3 FY23 | Q3 FY22 |
---|---|---|
Current Ratio | 2.07 | 4.86 |
Debt/Capital | 0.52 | 0.29 |
Interest Expense | 0.68 | 0.32 |
Interest Coverage | -14.82 | -35.27 |
Share Data | Q3 FY23 | Q3 FY22 |
---|---|---|
Shares outstanding (mil) | 29.98 | 29.52 |
Div / share | 0.0 | 0.0 |
EPS | -0.37 | -0.42 |
Book value / share | 1.55 | 1.81 |
Institutional Own % | n/a | n/a |
Avg Daily Volume | 701305.0 | 233466.0 |
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. For additional comparison, its price-to-book ratio of 0.33 indicates a significant discount versus the S&P 500 average of 4.68 and a significant discount versus the subsector average of 23.59. The price-to-sales ratio is well below both the S&P 500 average and the subsector average, indicating a discount. After reviewing these and other key valuation criteria, TELESIS BIO INC proves to trade at a discount to investment alternatives.
Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
TBIO NM | Peers 53.34 | TBIO NM | Peers 44.47 | |||||||||||||||||||||
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings. TBIO's P/E is negative making this valuation measure meaningless. |
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. TBIO's P/CF is negative making the measure meaningless. |
|||||||||||||||||||||||
Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
TBIO NM | Peers 26.06 | TBIO NA | Peers 1.95 | |||||||||||||||||||||
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings. TBIO's ratio is negative making this valuation measure meaningless. |
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. Ratio not available. |
|||||||||||||||||||||||
Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
TBIO 0.33 | Peers 23.59 | TBIO 27.78 | Peers 123.02 | |||||||||||||||||||||
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. TBIO is trading at a significant discount to its peers. |
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. However, TBIO is expected to significantly trail its peers on the basis of its earnings growth rate. |
|||||||||||||||||||||||
Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
TBIO 0.51 | Peers 14.13 | TBIO 42.56 | Peers 27.20 | |||||||||||||||||||||
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. TBIO is trading at a significant discount to its subsector on this measurement. |
Higher. A sales growth rate that exceeds the subsector implies that a company is gaining market share. TBIO has a sales growth rate that significantly exceeds its peers. |
|||||||||||||||||||||||